Lite Strategy (LITS) Liabilities and Shareholders Equity (2011 - 2026)
Lite Strategy (LITS) posted quarterly Liabilities and Shareholders Equity of $57.8 million for Q1 2026, up 178.11% year-over-year from $20.8 million in Q1 2025, and down 30.32% quarter-over-quarter from $82.9 million in Q4 2025.
Lite Strategy (LITS) Liabilities and Shareholders Equity (2011 - 2026) Analysis & Trends
Lite Strategy's Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $57.8 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 178.11% year-over-year to $57.8 million; the TTM figure through Mar 2026 stood at $272.3 million (up 138.3% YoY), while the FY2025 annual figure was $18.3 million, down 55.81% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $57.8 million, down from $82.9 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $194.4 million in Q1 2022, with the low at $18.3 million in Q2 2025.
- The 5-year median for Liabilities and Shareholders Equity is $82.9 million (2025), against an average of $92.7 million.
- The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity plunged 72.59% in 2024, then jumped 308.42% in 2025.
- Lite Strategy's Liabilities and Shareholders Equity stood at $147.6 million in 2022, then sank by 46.79% to $78.5 million in 2023, then plunged by 68.95% to $24.4 million in 2024, then jumped by 240.11% to $82.9 million in 2025, then sank by 30.32% to $57.8 million in 2026.
- Business Quant data shows LITS's Liabilities and Shareholders Equity at $57.8 million in Q1 2026, $82.9 million in Q4 2025, and $113.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - | 57.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57.79 Mn |
| Dec 31, 2025 | 82.94 Mn |
| Sep 30, 2025 | 113.34 Mn |
| Jun 30, 2025 | 18.29 Mn |
| Mar 31, 2025 | 20.78 Mn |
| Dec 31, 2024 | 24.39 Mn |
| Sep 30, 2024 | 27.75 Mn |
| Jun 30, 2024 | 41.38 Mn |
| Mar 31, 2024 | 71.26 Mn |
| Dec 31, 2023 | 78.54 Mn |
| Sep 30, 2023 | 101.25 Mn |
| Jun 30, 2023 | 120.81 Mn |
| Mar 31, 2023 | 134.19 Mn |
| Dec 31, 2022 | 147.60 Mn |
| Sep 30, 2022 | 163.58 Mn |
| Jun 30, 2022 | 177.84 Mn |
| Mar 31, 2022 | 194.43 Mn |
| Dec 31, 2021 | 209.46 Mn |
| Sep 30, 2021 | 176.35 Mn |
| Jun 30, 2021 | 174.10 Mn |